" class="no-js "lang="en-US"> James Sabry - Medtech Alert
Tuesday, April 16, 2024
James Sabry

James Sabry

About James Sabry

James is the Global Head And Executive Vice President of Roche Partnering, leading the combined groups from Roche and Genentech. He is also a member of the Roche enlarged Corporate Executive Committee. Prior to this he was Senior Vice President of Genentech Partnering. Prior to this, he was President and CEO of Arete Therapeutics as well as Chairman of the Board of Directors and former CEO of Cytokinetics, a company he co-founded in August 1997. He currently sits on Cytokinetics’ scientific advisory board. Prior to Cytokinetics, he held faculty positions at the University of California, San Francisco and Harvard Medical School. He served on the Board of Directors of HopeLab, a not-for-profit organization developing innovative technologies for the management of cancer, obesity and other diseases. He is a former member of Dean’s Council of the Kennedy School of Government at Harvard University and served on the advisory board of the California Institute of Quantitative Biosciences. He received an M.D. from Queen’s University and a Ph.D. in Neuroscience from the University of California, San Francisco.

His continued interests are in identifying,completing and managing drug discovery and development alliances that focus on novel targets and approaches to managing serious medical illness. In particular, he is interested in approaches that take into consideration the complexity and variation inherent in the human biological processes and putting the drug discovery process in an evolutionary context.

Related Story

Sysnav Healthcare Announces a Multi-year Collaboration with Roche

January 25 2023

Sysnav Healthcare and Roche enter a partnership to facilitate development of industry-standard outcome measurements in […]

Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader

August 18 2022

Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary […]

EarlySign Announces Strategic Collaboration Agreement with Roche on AI Solution for Early Detection of Lung Cancer

July 8 2022

Medial EarlySign (earlysign.com), a pioneering company developing Artificial Intelligence (AI) based clinical predictive analytics, announced today […]

KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses

May 24 2022

KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for […]